Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 10, 2000

View Archived Issues

ICN acquires three products from Wyeth-Pharma

Role for COX-2 in ischemic damage produced by NO

CRL-1072 enhances antibiotic activity against MAI

Merck describes novel penems with activity against resistant staphylococci

New series of NK2 receptor antagonists developed at Pfizer

Agents for improving insulin resistance designed by AHP scientists

Korean lab focuses on fumagillol derivatives as angiogenesis inhibitors

NC-1175 possesses ATPase-targeted antifungal activity

Centaur continues research into potential new treatments for IBD

Olanzapine and fluoxetine in combination useful for refractory depression

Rat adjuvant arthritis ameliorated by thalidomide analogue

The antiplatelet agent triflusal now shown to inhibit NF-kappaB activation

Sedative/hypnotic neuroactive steroids from CoCensys successfully pass preclinical screening

Abbott's new ketolide ABT-773 will be codeveloped by Taisho

Sumitomo to develop BDNF for new indication: diabetes

Health Canada approves first pill to treat influenza

Depot avorelin produces effective, sustained and safe medical castration in prostate cancer

FDA approves liquid formulation of Celexa for treatment of depression

Isis and Elan to develop antisense drug for HCV

Another major market launch announced for infliximab

BLA submitted for PEG-Intron HCV therapy

PR39 induces therapeutic angiogenesis in preclinical models

Inspire's dry eye product enters phase II testing

BioCryst updates influenza neuraminidase inhibitor program with R.W. Johnson

Qiagen acquires Rapigene

Adult patients with chronic liver disease respond poorly to HBV vaccines

Licensing opportunity from NIH: live attenuated RSV and PIV for use as human vaccines

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.